Clinical summary
Computer-aided detection-assisted colonoscopy: classification and relevance of false positives
Title | Computer-aided detection-assisted colonoscopy: classification and relevance of false positives |
First author | Cesare Hassan (Digestive Endoscopy, Nuovo Regina Margherita Hospital, Rome, Italy) |
Journal | Gastrointestinal Endoscopy |
Pub date | June 2020 (online), October 2020 (print) |
DOI | 10.1016/j.gie.2020.06.021 |
Evaluate the false positive (FP) images detected by computer-aided detection (CADe) to identify the cause and clinical relevance of the false positives.
Post-hoc analysis of FPs from images collected in the Artificial Intelligence for Colorectal Adenoma (AID) Study (Repici 2020). The study was a multicenter, randomized study where patients underwent colonoscopy, with and without CADe using GI Genius™ intelligent endoscopy module, for colorectal cancer screening, surveillance, or GI symptoms. 1092 FPs were evaluated in 40 consecutive videos from the CADe arm at one AID Study center.
False positives were adjudicated by a panel of four endoscopists, where each endoscopist described the cause of FP activation by GI Genius™ intelligent endoscopy module and the clinical relevance. >80% agreement on image assessment was required.
The mean number of FPs per colonoscopy was 27.3 ±13.1, of which 88% and 12% were due to artifacts in the bowel wall and bowel content, respectively. Of the 27.3 FPs per colonoscopy, 5.7% required additional exploration time of 4.8 ± 6.2 seconds per FP.
Clinical relevance considered time spent by the endoscopists reviewing a FP and the rate of FP per minute (withdrawal time only).
This analysis demonstrated that most CADe activations (false positives) are explained by folds (bowel wall artifacts), and that the additional review time caused by FPs is minimal.
US-DG-2100150 ©2021 Medtronic. All rights reserved. Medtronic, Medtronic logo and Further, Together are trademarks of Medtronic. All other brands are trademarks of a Medtronic company.
Disclaimer: All content from healthcare professionals is their individual conclusions, unless otherwise cited. All speaker or author engagement for content is noted to acknowledge funding from Covidien LP, a Medtronic company, for any consulting engagement.